Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Advancing Patient Care in Hypertrophic Cardiomyopathy: Key Insights from the HFA 2024
Author(s): Ahmad Masri , Added: 1 year ago
Recorded during HFA 2024, Dr Caroline Coats, Glasgow University, UK, and Dr Ahmad Masri, Oregon Health and Science University, US, collaborate to explore the pivotal advancements in managing hypertrophic cardiomyopathy unveiled at the conference.This programme is thoughtfully divided into four chapters, facilitating a smooth journey through the latest HCM trial data, including a comprehensive… View more

Guidelines & Statements

Heart Failure
Biological Aging, AI & the Brain-Heart Connection: A Conversation with Dr Valentin Fuster
Added: 1 year ago
In this exclusive episode of the "Innovations in Cardiology" podcast series, host Dr Dipti Itchhaporia, past president of the American College of Cardiology, delves into the latest advancements in cardiovascular health. She is joined by Dr Valentin Fuster, a pioneer in the field, who shares invaluable insights into the impact of biological ageing, the connection between the heart and brain, and… View more

Digital Health

Heart Failure
Vutrisiran Attenuates Cardiac Decline in ATTR-CM, HELIOS-B Analysis Shows
Added: 8 months ago Source:  Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal disease characterised by the deposition of amyloid fibrils in the heart. A new analysis from the HELIOS-B trial has found that key echocardiographic measures are strong predictors of clinical outcomes and that the RNA interference (RNAi) therapeutic vutrisiran attenuates the decline in cardiac function in this patient… View more

Imaging & Diagnostics

Heart Failure
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 1 year ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
STEP: Early Intensive BP Control Shows Long-Term Benefit
Added: 5 months ago Source:  Radcliffe Cardiology
New long-term data from the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial suggests that sustained, intensive blood pressure (BP) control provides greater cardiovascular benefits compared to a delayed approach in older patients with hypertension.¹ The findings also indicate that the earlier intensive treatment is initiated, the greater the reduction in… View more

Demographic

Heart Failure
ESC 25: The ODYSSEY-HCM Study
Author(s): Milind Y Desai Added: 7 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a… View more

Heart Failure
ESPRIT: Intensive BP Control Benefits Frail Patients
Added: 3 months ago Source:  Radcliffe Cardiology
Intensive blood pressure (BP) control is beneficial for high-risk hypertensive patients, regardless of their frailty status, according to a new post hoc analysis of the ESPRIT trial.¹ The findings suggest that even severely frail patients can safely achieve cardiovascular benefits from a lower systolic BP target.MethodologyThis analysis was conducted on data from the ESPRIT (Effects of intensive… View more

Demographic

Heart Failure
Time in Target Ambulatory Blood Pressure Range Linked to Lower CV Risk
Added: 8 months ago Source:  Radcliffe Cardiology
A new meta-analysis suggests that the more time an individual's ambulatory blood pressure (ABP) is within the target range proposed by the 2024 European Society of Cardiology (ESC) guidelines, the lower their risk of mortality and cardiovascular events.¹ The findings also highlight that office blood pressure measurements frequently misclassify patients with regard to their actual blood pressure… View more

Prevention & Chronic Conditions

Demographic
HFSA 25: The ATTRibute-CM Trial
Author(s): Ahmad Masri Added: 6 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more

Heart Failure
ESC 25: EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
Author(s): Ahran D Arnold Added: 7 months ago
ESC Congress 2025 - EMORI-HCM finds that right ventricular pacing (iRVP) improves symptoms in obstructive hypertrophic cardiomyopathy (oHCM) patients.Dr Ahran Arnold (Imperial College London, UK) discusses findings from the EMORI-HCM study, exploring electro-mechanically optimised right ventricular pacing as a novel therapeutic approach for patients with oHCM.This interventional trial examined… View more

Intervention

Electrophysiology & Arrhythmia